Loading...

Biotinylated Recombinant Human PD-L1 (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
CD274, Programmed cell death 1 ligand 1 (PD-L1), B7 homolog 1 (B7h1)
Ave. Rating
Submit a Review
Product Citations
publications
PD-L1_Human_BIOTIN-RECOM_1_BA_062823
Biotinylated recombinant human PD-L1 binds to immobilized recombinant human PD-1-Fc Chimera (Cat. No. 785102) in a dose-dependent manner. ED50 of this binding is 30 - 300 ng/mL.
  • PD-L1_Human_BIOTIN-RECOM_1_BA_062823
    Biotinylated recombinant human PD-L1 binds to immobilized recombinant human PD-1-Fc Chimera (Cat. No. 785102) in a dose-dependent manner. ED50 of this binding is 30 - 300 ng/mL.
Cat # Size Price Quantity Check Availability Save
561104 25 µg $410
Check Availability


Need larger quantities of this item?
Request Bulk Quote
561106 100 µg $825
Check Availability


Need larger quantities of this item?
Request Bulk Quote

Select size of product is eligible for a 40% discount! Promotion valid until December 31, 2024. Exclusions apply. To view full promotion terms and conditions or to contact your local BioLegend representative to receive a quote, visit our webpage.

Description

PD-L1 is a type I transmembrane protein of 290 amino acids, and it is a member of the B7 family. Human PD-L1 has 70% amino acid identity to its mouse orthologue. Binding of PD-L1 to its receptor PD-1 leads to the inhibition of T cell receptor–mediated lymphocyte proliferation and cytokine secretion. PD-L1 induces IL-10 production in T cells stimulated with low levels of anti-CD3. PD-L1/PD-1 interaction suppresses immune responses against autoantigens and tumors and plays an important role in the maintenance of peripheral immune tolerance. Disruption of the PD-L1 gene leads to up-regulated T cell responses and the generation of self-reactive T cells. Antibodies against PD-1 or PD-L1 leads to increased antitumor immunity. PD-L1 has an important role in conferring fetomaternal tolerance in an allogeneic pregnancy model; antibodies against PD-L1 lead to a breakdown in maternal tolerance to the fetus. PD-L1 shares its receptor with PD-L2 (CD273, B7-DC). PD-L2 has a more limited expression than PD-L1, being expressed on activated macrophages and dendritic cells. PD-L1 is expressed in many tumors, and the interaction with its receptor activates signaling pathways that inhibit T-cell activity and therefore the antitumor immune response. Antibodies targeting PD-1 or PD-L1 block the PD-1 pathway and reactivate T cell activity.

Product Details
Technical data sheet

Product Details

Source
Biotinylated recombinant human PD-L1, amino acid (Phe19-Arg238) (Accession # Q9NZQ7.1), with a linker (AAANSSLGS), a C-terminal human IgG1 (Pro100-Lys330) and an Avi-tag, was expressed in CHO cells. Human PD-L1-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass
The 472 amino acid recombinant protein has a predicted molecular mass of approximately 53.7 kD. The DTT-reduced and non-reduced protein migrates at approximately 70 kD and 140 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Phe.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in PBS, 5% glycerol
Endotoxin Level
Less than 0.1 EU per µg cytokine as determined by the LAL method.
Concentration
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
Biotinylated recombinant human PD-L1 binds to immobilized recombinant human PD-1-Fc Chimera (Cat. No. 785102) in a dose-dependent manner. ED50 of this binding is 30 - 300 ng/mL.
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Disulfide bond-linked homodimer
Distribution

APC, monocytes, dendritic cells, expressed in nonlymphoid tissues, and stromal cell

Function
Enhances CD28-independent T-helper cell function, suppresses immune responses against autoantigens, and participates in fetomaternal tolerance
Interaction
Antigen-stimulated T and B cells, regulatory T cells, follicular T and B cells, dendritic cells, and monocytes
Ligand/Receptor
PD-1 (CD279)
Bioactivity
Biotinylated recombinant human PD-L1 binds to immobilized recombinant human PD-1-Fc Chimera (Cat. No. 785102) in a dose-dependent. ED50 of this binding is 30 - 300 ng/mL.
Cell Type
Antigen-presenting cells, Dendritic cells, Monocytes
Biology Area
Cell Proliferation and Viability, Immuno-Oncology, Immunology
Molecular Family
CD Molecules
Antigen References
  1. Dong H, et al. 1999. Nat Med. 5:1365-9.
  2. Freeman GJ, et al. 2000. J Exp Med. 192:1027-34.
  3. Latchman Y, et al. 2001. Nat Immunol. 2:261-8.
  4. Latchman YE, et al. 2004. Proc Natl Acad Sci U S A. 101:10691-6.
  5. Guleria I, et al. 2005. J Exp Med. 202:231-7.
  6. Lin DY, et al. 2008. Proc Natl Acad Sci U S A. 105:3011-6.
  7. Dai S, et al. 2014. Cell Immunol. 290:72-9.
  8. Melero I, et al. 2015. Nat Rev Cancer. 15:457-72.
Gene ID
29126 View all products for this Gene ID
UniProt
View information about PD-L1 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 01/24/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account